Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zymenex's Lamazym advances to phase II in alpha-mannosidosis

Feb. 3, 2011

New GPR119 receptor agonists presented

Feb. 3, 2011

Prolia available in Quebec for postmenopausal osteoporosis

Feb. 3, 2011

New bombesin BB3 receptor agonist MK-5046 shows preclinical potential to treat obesity

Feb. 3, 2011

FDA requests additional trial of Contrave

Feb. 2, 2011

Lixisenatide demonstrates noninferiority to exenatide in phase III GetGoal-X trial

Feb. 2, 2011

BioMarin begins phase III trial of N-acetylgalactosamine 6-sulfatase in MPS IVA

Feb. 2, 2011

Phase IIb follow-up data show efficacy of KUR-111 in bone regeneration

Feb. 2, 2011

AMT receives grant to develop AMT-021 for acute intermittent porphyria

Jan. 31, 2011

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Jan. 27, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...